Document Detail

Coronary thrombolysis: progress and promise.
MedLine Citation:
PMID:  6084148     Owner:  NLM     Status:  MEDLINE    
The therapeutic history of thrombolysis in coronary heart disease is relatively recent, but is now stimulating rapidly increasing interest. Studies of the evolution of acute coronary thrombosis demonstrate the urgent necessity to commence thrombolysis treatment at the earliest possible moment. The development of newer specific thrombolytic agents with low toxicity, without antigenicity, and available for rapid parenteral administration holds much promise for the treatment of acute myocardial infarction in the future.
B E Sobel
Related Documents :
9604968 - Impact of injection rate on the thrombolysis in myocardial infarction (timi) trial fram...
11322908 - Noninvasive transcutaneous low frequency ultrasound enhances thrombolysis in peripheral...
14752128 - Systemic thrombolysis with recombinant tissue plasminogen activator and tirofiban in ac...
16721208 - Electrocardiographic abnormalities mimicking myocardial infarction in a patient with in...
23861498 - Rupture of the left atrial roof due to blunt trauma.
9415008 - Right ventricular dysfunction during coronary artery occlusion: pressure-volume analysi...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of cardiovascular pharmacology     Volume:  6 Suppl 6     ISSN:  0160-2446     ISO Abbreviation:  J. Cardiovasc. Pharmacol.     Publication Date:  1984  
Date Detail:
Created Date:  1985-03-18     Completed Date:  1985-03-18     Revised Date:  2004-11-17    
Medline Journal Info:
Nlm Unique ID:  7902492     Medline TA:  J Cardiovasc Pharmacol     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  S910-3     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Coronary Disease / drug therapy*,  physiopathology
Fibrinolytic Agents / adverse effects,  therapeutic use*
Peptide Hydrolases / therapeutic use
Streptokinase / therapeutic use
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.-/Peptide Hydrolases; EC 3.4.-/Streptokinase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Arrhythmias associated with reperfusion: basic insights and clinical relevance.
Next Document:  Secondary prevention after myocardial infarction: facts and fallacies.